NASDAQ:OVIDOvid Therapeutics Stock Price, Forecast & News

Ovid Therapeutics' stock was trading at $2.68 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, OVID stock has increased by 185.1% and is now trading at $7.64.
View which stocks have been most impacted by COVID-19.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Ovid Therapeutics.

Ovid Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, November 13th 2020.
View our earnings forecast for Ovid Therapeutics.

Ovid Therapeutics Inc (NASDAQ:OVID) announced its quarterly earnings results on Monday, August, 10th. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by $0.05.
View Ovid Therapeutics' earnings history.

8 brokers have issued 12 month price objectives for Ovid Therapeutics' stock. Their forecasts range from $9.00 to $21.00. On average, they expect Ovid Therapeutics' stock price to reach $13.33 in the next year. This suggests a possible upside of 74.5% from the stock's current price.
View analysts' price targets for Ovid Therapeutics.

Media coverage about OVID stock has been trending positive recently, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Ovid Therapeutics earned a media sentiment score of 2.7 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near future.
View the latest news about Ovid Therapeutics.

Ovid Therapeutics saw a increase in short interest in the month of June. As of June 15th, there was short interest totaling 1,340,000 shares, an increase of 58.6% from the May 31st total of 844,800 shares. Based on an average daily volume of 1,230,000 shares, the short-interest ratio is presently 1.1 days. Currently, 4.6% of the shares of the company are short sold.
View Ovid Therapeutics' Short Interest.

Some companies that are related to Ovid Therapeutics include INDIVIOR PLC/S (INVVY), Seres Therapeutics (MCRB), ALX Oncology (ALXO), Rocket Pharmaceuticals (RCKT), Myovant Sciences (MYOV), Dicerna Pharmaceuticals (DRNA), MacroGenics (MGNX), Heron Therapeutics (HRTX), ZEALAND PHARMA/S (ZEAL), Portola Pharmaceuticals (PTLA), Akebia Therapeutics (AKBA), Innoviva (INVA), Zymeworks (ZYME), Zogenix (ZGNX) and Amneal Pharmaceuticals (AMRX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ovid Therapeutics investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Viking Therapeutics (VKTX), Gilead Sciences (GILD), VBI Vaccines (VBIV) and Selecta Biosciences (SELB).

(OVID) raised $80 million in an IPO on Friday, May 5th 2017. The company issued 5,000,000 shares at $15.00-$17.00 per share. Citigroup and Cowen and Company served as the underwriters for the IPO and William Blair and JMP Securities were co-managers.

Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID."

Ovid Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include FMR LLC (3.25%), CHI Advisors LLC (0.99%), Assenagon Asset Management S.A. (0.93%), Platinum Investment Management Ltd. (0.55%), UBS Group AG (0.24%) and Bank of New York Mellon Corp (0.22%). Company insiders that own Ovid Therapeutics stock include Douglas E Williams, Jeremy M Levin, Karen Bernstein and Pharmaceutical Co Ltd Takeda.
View institutional ownership trends for Ovid Therapeutics.

OVID stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, CHI Advisors LLC, Platinum Investment Management Ltd., UBS Group AG, and Goldman Sachs Group Inc..
View insider buying and selling activity for Ovid Therapeutics.

OVID stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Bank of New York Mellon Corp, California Public Employees Retirement System, Virtus ETF Advisers LLC, New York State Common Retirement Fund, American International Group Inc., SG Americas Securities LLC, and State Board of Administration of Florida Retirement System. Company insiders that have bought Ovid Therapeutics stock in the last two years include Douglas E Williams, Jeremy M Levin, Karen Bernstein, and Pharmaceutical Co Ltd Takeda.
View insider buying and selling activity for Ovid Therapeutics.

Shares of OVID can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of OVID stock can currently be purchased for approximately $7.64.

Ovid Therapeutics has a market capitalization of $436.11 million. The company earns $-60,460,000.00 in net income (profit) each year or ($1.54) on an earnings per share basis. Ovid Therapeutics employs 59 workers across the globe.

The official website for Ovid Therapeutics is www.ovidrx.com.

Ovid Therapeutics' mailing address is 1460 Broadway Suite 15044, New York NY, 10036. The company can be reached via phone at 646-661-7661 or via email at [email protected]